Hey D The 1% refers to the number of patients who could not be analysed by the App in the new FDA trial. The previous 70% from the first FDA is the total number of 'coughs' results that were effected for various reasons. If 70% of patients presenting were excluded the App would be worthless. I hope this helps.
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Provides SMARTCOUGH-C-2 Study Update
Ann: ResApp Provides SMARTCOUGH-C-2 Study Update, page-39
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online